{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Silins I"],"funding":["Akademiska Sjukhuset","Uppsala University","Medical Research Council","Medical Research Council of the United Kingdom"],"pagination":["398-409"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9816205"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50(2)"],"pubmed_abstract":["<h4>Purpose</h4>[<sup>11</sup>C]Metomidate positron emission tomography (PET) is currently used for staging of adrenocortical carcinoma and for lateralization in primary aldosteronism (PA). Due to the short half-life of carbon-11 and a high non-specific liver uptake of [<sup>11</sup>C]metomidate there is a need for improved adrenal imaging methods. In a previous pre-clinical study para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate has been proven to be a specific adrenal tracer. The objective is to perform a first evaluation of para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate positron emission computed tomography ([<sup>18</sup>F]CETO-PET/CT) in patients with adrenal tumours and healthy volunteers.<h4>Methods</h4>Fifteen patients underwent [<sup>18</sup>F]CETO-PET/CT. Five healthy volunt"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["First-in-human evaluation of [&lt;sup&gt;18&lt;/sup&gt;F]CETO: a novel tracer for adrenocortical tumours."],"pmcid":["PMC9816205"],"funding_grant_id":["MR/P01710X/1"],"pubmed_authors":["Antoni G","Brown M","Wall A","Aigbirhio F","Silins I","Lubberink M","O'Sullivan L","Gurnell M","Roslin S","Sundin A","Hellman P","Akerstrom T"],"additional_accession":[]},"is_claimable":false,"name":"First-in-human evaluation of [&lt;sup&gt;18&lt;/sup&gt;F]CETO: a novel tracer for adrenocortical tumours.","description":"<h4>Purpose</h4>[<sup>11</sup>C]Metomidate positron emission tomography (PET) is currently used for staging of adrenocortical carcinoma and for lateralization in primary aldosteronism (PA). Due to the short half-life of carbon-11 and a high non-specific liver uptake of [<sup>11</sup>C]metomidate there is a need for improved adrenal imaging methods. In a previous pre-clinical study para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate has been proven to be a specific adrenal tracer. The objective is to perform a first evaluation of para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate positron emission computed tomography ([<sup>18</sup>F]CETO-PET/CT) in patients with adrenal tumours and healthy volunteers.<h4>Methods</h4>Fifteen patients underwent [<sup>18</sup>F]CETO-PET/CT. Five healthy volunt","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-27T23:14:52.48Z","creation":"2024-12-04T12:40:47.955Z"},"accession":"S-EPMC9816205","cross_references":{"pubmed":["36074157"],"doi":["10.1007/s00259-022-05957-9"]}}